Search results
Results from the WOW.Com Content Network
This page was last edited on 9 February 2024, at 00:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP). It is a member of the larger family of PDE inhibitors .
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
Pages in category "PDE4 inhibitors" The following 23 pages are in this category, out of 23 total. This list may not reflect recent changes. ...
Pages in category "Phosphodiesterase inhibitors" The following 40 pages are in this category, out of 40 total. This list may not reflect recent changes. *
At least four types of the enzyme phosphodiesterase 4 (PDE4) are known: PDE4A; ... See also. 3',5'-cyclic-AMP phosphodiesterase; Phosphodiesterase (PDE) PDE4 inhibitor
[3] [4] The potential for selective phosphodiesterase inhibitors to be used as therapeutic agents was predicted in the 1970s by Weiss and coworkers. [5] This prediction has now come to pass in a variety of fields (e.g. sildenafil as a PDE5 inhibitor and Rolipram as a PDE4 inhibitor).
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [4] It is taken by mouth. [4]